Development, validation, and comparison of gene analysis methods for detecting
circulating free DNA
epidermal growth factor receptor mutation
epidermal growth factor receptor-tyrosine kinase inhibitor
non-small cell lung cancer
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
04 Jun 2019
04 Jun 2019
Historique:
received:
13
09
2018
accepted:
04
05
2019
entrez:
21
6
2019
pubmed:
21
6
2019
medline:
21
6
2019
Statut:
epublish
Résumé
The feasibility and required sensitivity of circulating free DNA (cfDNA)-based detection methods in second-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment are not well elucidated. We examined T790M and other activating mutations of
Identifiants
pubmed: 31217900
doi: 10.18632/oncotarget.26951
pii: 26951
pmc: PMC6557207
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3654-3666Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Akira Kanoh and Takuya Kuramoto received remuneration from Taiho Pharmaceutical Co., Ltd. Tatsuro Saito received remuneration from Riken Genesis Co., Ltd. Kenji Otsuka holds stocks of Otsuka Holdings Co., Ltd. Hiroshi Nokihara and Yasuhiko Nishioka received grants and personal fees from Taiho Pharmaceutical Co., Ltd. Masaki Hanibuchi, Makoto Tobiume, Atsuro Saijo, Hiroyuki Kozai, Mayo Kondo, Shun Morizumi, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Seidai Sato, Hiroshi Kawano, Yuko Toyoda and Hisatsugu Goto had no financial and personal relationships with other people or organizations that could inappropriately influence the submitted work.
Références
Cancer Sci. 2007 Dec;98(12):1817-24
pubmed: 17888036
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
Anal Biochem. 2011 Jan 15;408(2):197-205
pubmed: 20850410
J Thorac Oncol. 2012 Jan;7(1):115-21
pubmed: 21900837
J Clin Oncol. 2012 Feb 1;30(4):433-40
pubmed: 22215752
J Thorac Dis. 2011 Mar;3(1):10-8
pubmed: 22263058
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
Cancer. 2013 Dec 15;119(24):4325-32
pubmed: 24105277
Cancer Res. 2013 Nov 1;73(21):6384-8
pubmed: 24145355
Clin Chim Acta. 2014 Feb 15;429:8-11
pubmed: 24269715
PLoS One. 2013 Nov 21;8(11):e81468
pubmed: 24278442
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Sci Rep. 2014 Sep 09;4:6269
pubmed: 25201768
Lung Cancer. 2014 Nov;86(2):170-3
pubmed: 25214431
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
Ann Oncol. 2015 Sep;26(9):1877-83
pubmed: 26141208
Lung Cancer. 2016 Apr;94:68-73
pubmed: 26973209
J Hematol Oncol. 2016 Jul 22;9(1):59
pubmed: 27448564
Cancer Sci. 2016 Nov;107(11):1660-1666
pubmed: 27575703
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Expert Rev Mol Diagn. 2017 Mar;17(3):209-215
pubmed: 28129709
BMC Cancer. 2017 Mar 22;17(1):210
pubmed: 28330468
J Nucl Med. 2017 Nov;58(11):1764-1769
pubmed: 28450567
Theranostics. 2017 Apr 2;7(6):1437-1446
pubmed: 28529628
Mol Med Rep. 2017 Aug;16(2):1157-1166
pubmed: 29067441